CD33
CD33 is a myeloid marker and the target of the very first ADC ever approved, in 2000.
Gemtuzumab ozogamicin against CD33 was approved in 2000, withdrawn in 2010, and re-approved in 2017 with fractionated dosing, an object lesson in ADC development.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CD33 is a myeloid marker and the target of the very first ADC ever approved, in 2000.
- 1 · What it is
CD33 is a myeloid marker and the target of the very first ADC ever approved, in 2000.
- 2 · What goes wrong in cancer
Siglec-3; expressed on AML blasts and normal myeloid cells.
- 3 · How drugs use it
1 product aims at CD33: antibody-drug conjugates. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Biology
Siglec-3; expressed on AML blasts and normal myeloid cells.
- Acute myeloid leukaemia
How common it is, by cancer
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Acute myeloid leukaemia | 85-90% | Blast surface expression | Wikipedia |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Latest papers
topQuery for this target: (TITLE:"CD33" OR ABSTRACT:"CD33") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD33, not a curated reading list.